Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
CID44216842
Cat. No.:
OB0225LY-0047
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
CID44216842 is a high-purity Cdc42-selective guanine nucleotide binding lead inhibitor.
Synonym:
KUC103479N-02; 1222513-26-9; 4-[3-(4-Bromophenyl)-5-(3-methoxyphenyl)-3,4-dihydropyrazol-2-yl]benzenesulfonamide; 4-[5-(4-Bromophenyl)-3-(3-methoxyphenyl)-2-pyrazolin-1-yl]benzenesulfonamide; 4-(5-(4-Bromophenyl)-3-(3-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide
CAS No.:
1222513-26-9
Compound CID:
44216842
Formula:
C22H20BrN3O3S
Formula Weight:
486.38
Specification
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
CID44216842 is commonly used in drug screening and mechanistic studies.
Library Information
Targets:
Ras; CDK
Receptors:
Cdc42
Pathways:
GPCR/G protein; MAPK; Cell cycle/Checkpoint
Plate Number:
AOCL-1
Plate Location:
e9
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
250 mg/mL; 514.00 mM
